Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy
(Reuters) -The Senate Committee on Health, Education, Labor, and Pensions said on Friday that Novo Nordisk CEO Lars Jorgensen has agreed to testify voluntarily in a hearing focusing on U.S. prices for weight loss drugs Ozempic and Wegovy. A U.S. Senate health panel vote that was scheduled for its June 18 meeting, to decide whether…